Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: A safe and effective therapy?
- 1 January 2005
- journal article
- case report
- Published by Elsevier in Gastroenterology
- Vol. 128 (1), 164-168
- https://doi.org/10.1053/j.gastro.2004.09.005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant databaseLiver Transplantation, 2004
- Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective studyHepatology, 2003
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Pulmonary Hemodynamics and Perioperative Cardiopulmonary-Related Mortality in Patients With Portopulmonary Hypertension Undergoing Liver TransplantationLiver Transplantation, 2000
- Gene Expression of Endothelin-1 and ETA and ETB Receptors in Human Cirrhosis: Relationship with Hepatic HemodynamicsJournal of Vascular Research, 1998
- Hepatopulmonary syndrome versus portopulmonary hypertension: Distinctions and dilemmasHepatology, 1997
- Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic ratsLife Sciences, 1995
- Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function†Hepatology, 1995
- Elevated circulating plasma endothelin-1 concentrations in cirrhosisJournal of Hepatology, 1993